As Artificial Intelligence (AI) and Machine Learning (ML) continue to reshape our industry, the conversation is shifting toward practical integration. Our CEO, Alexander Seyf, recently sat down with Pharmaceutical Technology to discuss how these tools are empowering scientists and manufacturers to work more effectively.

His perspective highlights a crucial balance: AI isn’t here to replace human expertise, but to accelerate human-led innovation by handling the “mechanical” burdens of modern science.

Key highlights from the interview include:

👉 AI and ML are best utilized to handle the heavy “mechanical” legwork, freeing human researchers to focus their intellectual efforts on high-level strategy and discovery.

👉 We are seeing a powerful trend in “cross-fertilization,” where AI identifies new indications for existing off-the-shelf drugs that were not originally intended for those treatments.

👉 Machine learning acts as a catalyst for drug discovery, helping scientists map biological progression and find solutions for diseases that currently have no known treatment.

👉 These technologies serve as essential supporting elements that help the industry move in the right direction by automating data-heavy processes.

See the full interview here.